|
Hemato-oncology
Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
Yundeok Kim, Tae-Hwa Go, Jaeyeon Jang, Jii Bum Lee, Seung Taek Lim, Kwang Yong Shim, Jong In Lee, Jee Hyun Kong
Korean J Intern Med. 2021;36(6):1450-1458. Published online November 1, 2021
Background/Aims: Adherence to tyrosine kinase inhibitors (TKIs) has become a critical aspect of care in chronic myeloid leukemia (CML). We aimed to examine the association of TKI adherence with overall survival (OS) outcomes in Korean patients diagnosed with CML and treated with TKIs using data from..
|
|
|
2020 Korean guidelines for the management of metastatic prostate cancer
In-Ho Kim, Sang Joon Shin, Byung Woog Kang, Jihoon Kang, Dalyong Kim, Miso Kim, Jin Young Kim, Chan Kyu Kim, Hee-Jun Kim, Chi Hoon Maeng, Kwonoh Park, Inkeun Park, Woo Kyun Bae, Byeong Seok Sohn, Min-Young Lee, Jae Lyun Lee, Junglim Lee, Seung Taek Lim, Joo Han Lim, Hyun Chang, Joo Young Jung, Yoon Ji Choi, Young Seok Kim, Jaeho Cho, Jae Young Joung, Se Hoon Park, Hyo Jin Lee
Korean J Intern Med. 2021;36(3):491-514. Published online February 10, 2021
In 2017, Korean Society of Medical Oncology (KSMO) published the Korean management guideline of metastatic prostate cancer. This paper is the 2nd edition of the Korean management guideline of metastatic prostate cancer. We updated recent many changes of management in metastatic prostate cancer in th..
|
|
|
Hemato-oncology
Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee
Moon Jin Kim, Young Sam Kim, Sung Yong Oh, Suee Lee, Young-Jin Choi, Young Mi Seol, Min Jae Park, Ki Hyang Kim, Lee Chun Park, Jung Hun Kang, In-Gyu Hwang, Soon Il Lee, Seung Taek Lim, Hyo Song Kim, Ho Yeong Lim, Sun Young Rha, Hyo-Jin Kim
Korean J Intern Med. 2018;33(2):383-390. Published online April 6, 2016
Background/Aims: Because of rarity, role of chemotherapy of bladder adenocarcinoma are still unidentified. Therefore, we performed a retrospective analysis of the clinical features and chemotherapy outcomes of bladder adenocarcinoma.
Methods: Eligible patients for this retrospective analysis were i..
|
|
|
